More Neurizon Therapeutics Limited news
Neurizon Therapeutics LimitedASX: NUZ

PharmAust Progresses Monepantel Tablet Program for Cancer

Oct 14, 2018 at 11:13 PM EDT · Issued by Neurizon Therapeutics Limited

Filed with ASX · Oct 14, 2018 at 11:13 PM EDT · 1 page · English

On 6ix: 6ix.com/news/pharmaust-progresses-monepantel-tablet-program-for-cancer

Neurizon Therapeutics Limited on 6ix

Story so far

  • Olivia Newton-John Cancer Reseach Institute collaborationSep 10, 2018
  • New MPL analogues show greater anti-cancer activityNov 23, 2017
  • New drugs patented for cancer in USANov 16, 2017

Earlier from Neurizon Therapeutics

  • Olivia Newton-John Cancer Reseach Institute collaborationSep 10, 2018
  • Reformulation of MPL into tablet form for upcoming trialsSep 3, 2018
  • Appendix 4C & Company Update - June 18Jul 31, 2018
  • Epichem gains prestigious international ISO accreditationJul 1, 2018
  • Epichem Awarded Major US Drug Discovery Contract ExtensionJun 6, 2018

Later from Neurizon Therapeutics

  • PharmAust Develops GMP Method for Monepantel AnaloguesOct 28, 2018
  • Appendix 4C & Company Update - Sep 2018Oct 31, 2018
  • GMP Tablet Manufacture Commences for Canine Clinical TrialsNov 12, 2018
  • PharmAust Develops Method for MPL/Analogue ManufactureDec 2, 2018
  • Monepantel Principal Metabolite Shows Anti-Cancer ActivityJan 13, 2019
All Neurizon Therapeutics news releases↗

Follow Neurizon Therapeutics into a list and get an email when it puts out news.

Follow Neurizon Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer